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REPLY 
I was pleased that Alstadt and Eaglstein found the recent article 
by Takashima and myself to be of interest and have answered 
their questions below. 
A. We have not tested carefully whether fibronectin plays a 
role in the initiation of keratinocyte migration out of explants. It 
has been our experience, however, that only about 25% of ex-
plants set up with fibronectin-depleted serum exhibit migration 
of cells from all around the explant compared with 60-70% of 
the explants cultured in fibronectin-containing medium. 
B. The level of antifibronectin antibodies was chosen based 
upon preliminary studies in which this concentration was found 
to inhibit keratinocyte attachment and spreading on fibronectin-
coated substrata. This antibody is an IgG preparation but not 
affinity purified, and we do not know the ratio of antibody mol-
ecules to fibronectin molecules . Such antibody levels do not seem 
excessive since similar concentrations also have been shown to 
be required to inhibit adhesion of fibroblasts to fibronectin [1] , 
and nonimmune IgG at similar or higher concentrations had no 
effect. 
C. We have not studied the effect of fibronectin on epidermal 
cell mitosis, but Gilchrest et al demonstrated that fibronectin 
markedly increased keratinocyte plating efficiency [2] . 
D . Fibronectin receptor function appeared on day 2 as measured 
by the bead binding assay, which we have shown previously to 
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be a more sensitive measure of receptors than cell attachment and 
spreading [3] . 
Finally, I should mention that the onset of fibronectin receptor 
function during wound healing in vivo has been described in a 
paper by Takashima, Billingham, and myself [4]. 
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Cytokine from Basal Cell Carcinomas Stimulates Collagenase Production 
To the Editor: 
The article "Stimulation of Skin Fibroblast Collagenase Produc-
tion by a Cytokine Derived from Basal Cell Carcinomas" by 
Goslen, Eisen, and Bauer (85:161-164, 1985) has provoked great 
interest on this Continent where these cancers are extraordinarily 
common. We would like to congratulate the authors on their 
findings and to add in a small way, as yet unpublished, the sta-
tistical fact that in the superficial cicatrising basal cell carcinoma 
(BCC) there is much less stimulation of fibroblast collagenase. 
We have not used as sophisticated methods as the authors but 
will do so and expect to confirm this. 
It is expected with respect to the superficial cicatrising BCC, 
that whilst inner areas of fibroblasts are not stimulated by cy-
tokines, some of those at the edge are influenced by external 
cytokines and hence the notorious incidence of recurrence in this 
type of cancer, which is well known and often termed "field 
effect carcinogenesis. " We would like to know if the authors used 
any superficial cicatrising BCCs for their source material and, 
second, if they have any comment to make about the fibroblasts 
accompanying the superficial fibrotic (cicatrising) BCC, since the 
morphoeic BCC is often confused with the latter in the literature. 
In our fmdings this has not been the case. In other words, the 
superficial BCC should not be histologically or biologically equalled 
with the morphoeic BCC which behaves much more in the fash-
ion as described by authors Goslen, Eisen, and Bauer. 
Malcolm Lane-Brown, B.Sc., M .B . , B.S., F.A.C.D . 
Sydney, N .S.W., Australia 
Paul Forlot, Ph. D. 
Paris, France 
REPLY 
We have read, with interest, the comments by Drs. Lane-Brown 
and Forlot regarding our recent publication in The Journal oj In-
vestigative Dermatology (May 1985, pp 161-164) . Our study in-
volved nodular basal cell carcinomas and did not involve any 
superficial fibrotic or morpheaform basal cell carcinomas. There-
fore, we have no particular insights to the questions the authors 
raise in their letter. Obviously, it is our hope to investigate these 
tumors in the future as they do represent an intriguing aspect of 
epithelial cancer-matrix interacation. 
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